超長時間作用性ベータ刺激薬のグローバル市場インサイト・予測（～2028年）

• 英文タイトル：Global Ultra Long Acting Beta Agonist Market Insights, Forecast to 2028

• レポートコード：QY2207E10506 • 出版社/出版日：QYResearch / 2022年7月 • レポート形態：英文、PDF、93ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥725,200 (USD4,900)	▷ お問い合わせ
Multi User	￥1,087,800 (USD7,350)	▷ お問い合わせ
Enterprise License	￥1,450,400 (USD9,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

新型コロナウイルス感染症のパンデミックにより、世界の超長時間作用性ベータ刺激薬の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に超長時間作用性ベータ刺激薬の世界市場のxxx％を占める「液体」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「病院」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 中国の超長時間作用性ベータ刺激薬の市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの超長時間作用性ベータ刺激薬市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの超長時間作用性ベータ刺激薬市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 超長時間作用性ベータ刺激薬のグローバル主要メーカーには、Sumitomo Dainippon Pharma、AstraZeneca、GlaxoSmithKline、Boehringer Ingelheim International、Mylan、Teva、Merckなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 超長時間作用性ベータ刺激薬市場は、種類と用途によって区分されます。世界の超長時間作用性ベータ刺激薬市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。 【種類別セグメント】 液体、錠剤 【用途別セグメント】 病院、クリニック、外来手術センター、その他 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 超長時間作用性ベータ刺激薬製品概要 - 種類別市場（液体、錠剤） - 用途別市場（病院、クリニック、外来手術センター、その他） - 調査の目的 ・エグゼクティブサマリー - 世界の超長時間作用性ベータ刺激薬販売量予測2017-2028 - 世界の超長時間作用性ベータ刺激薬売上予測2017-2028 - 超長時間作用性ベータ刺激薬の地域別販売量 - 超長時間作用性ベータ刺激薬の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別超長時間作用性ベータ刺激薬販売量 - 主要メーカー別超長時間作用性ベータ刺激薬売上 - 主要メーカー別超長時間作用性ベータ刺激薬価格 - 競争状況の分析 - 企業M&A動向 ・種類別市場規模（液体、錠剤） - 超長時間作用性ベータ刺激薬の種類別販売量 - 超長時間作用性ベータ刺激薬の種類別売上 - 超長時間作用性ベータ刺激薬の種類別価格 ・用途別市場規模（病院、クリニック、外来手術センター、その他） - 超長時間作用性ベータ刺激薬の用途別販売量 - 超長時間作用性ベータ刺激薬の用途別売上 - 超長時間作用性ベータ刺激薬の用途別価格 ・北米市場 - 北米の超長時間作用性ベータ刺激薬市場規模（種類別、用途別） - 主要国別の超長時間作用性ベータ刺激薬市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの超長時間作用性ベータ刺激薬市場規模（種類別、用途別） - 主要国別の超長時間作用性ベータ刺激薬市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の超長時間作用性ベータ刺激薬市場規模（種類別、用途別） - 主要国別の超長時間作用性ベータ刺激薬市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の超長時間作用性ベータ刺激薬市場規模（種類別、用途別） - 主要国別の超長時間作用性ベータ刺激薬市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの超長時間作用性ベータ刺激薬市場規模（種類別、用途別） - 主要国別の超長時間作用性ベータ刺激薬市場規模（トルコ、サウジアラビア） ・企業情報 Sumitomo Dainippon Pharma、AstraZeneca、GlaxoSmithKline、Boehringer Ingelheim International、Mylan、Teva、Merck ・産業チェーン及び販売チャネル分析 - 超長時間作用性ベータ刺激薬の産業チェーン分析 - 超長時間作用性ベータ刺激薬の原材料 - 超長時間作用性ベータ刺激薬の生産プロセス - 超長時間作用性ベータ刺激薬の販売及びマーケティング - 超長時間作用性ベータ刺激薬の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 超長時間作用性ベータ刺激薬の産業動向 - 超長時間作用性ベータ刺激薬のマーケットドライバー - 超長時間作用性ベータ刺激薬の課題 - 超長時間作用性ベータ刺激薬の阻害要因 ・主な調査結果

Market Analysis and Insights: Global Ultra Long Acting Beta Agonist Market
Due to the COVID-19 pandemic, the global Ultra Long Acting Beta Agonist market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, Liquid accounting for % of the Ultra Long Acting Beta Agonist global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospitals segment is altered to an % CAGR throughout this forecast period.
China Ultra Long Acting Beta Agonist market size is valued at US$ million in 2021, while the US and Europe Ultra Long Acting Beta Agonist are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Ultra Long Acting Beta Agonist landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
The global key manufacturers of Ultra Long Acting Beta Agonist include Sumitomo Dainippon Pharma, AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim International, Mylan, Teva and Merck, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Ultra Long Acting Beta Agonist Scope and Segment
Ultra Long Acting Beta Agonist market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Ultra Long Acting Beta Agonist market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Liquid
Tablet
Segment by Application
Hospitals
Clinics
Ambulatory Surgical Center
Others
By Company
Sumitomo Dainippon Pharma
AstraZeneca
GlaxoSmithKline
Boehringer Ingelheim International
Mylan
Teva
Merck
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

レポート目次

---

1 Study Coverage
1.1 Ultra Long Acting Beta Agonist Product Introduction
1.2 Market by Type
1.2.1 Global Ultra Long Acting Beta Agonist Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Liquid
1.2.3 Tablet
1.3 Market by Application
1.3.1 Global Ultra Long Acting Beta Agonist Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Ambulatory Surgical Center
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Ultra Long Acting Beta Agonist Sales Estimates and Forecasts 2017-2028
2.2 Global Ultra Long Acting Beta Agonist Revenue Estimates and Forecasts 2017-2028
2.3 Global Ultra Long Acting Beta Agonist Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Ultra Long Acting Beta Agonist Sales by Region
2.4.1 Global Ultra Long Acting Beta Agonist Sales by Region (2017-2022)
2.4.2 Global Sales Ultra Long Acting Beta Agonist by Region (2023-2028)
2.5 Global Ultra Long Acting Beta Agonist Revenue by Region
2.5.1 Global Ultra Long Acting Beta Agonist Revenue by Region (2017-2022)
2.5.2 Global Ultra Long Acting Beta Agonist Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Ultra Long Acting Beta Agonist Sales by Manufacturers
3.1.1 Global Top Ultra Long Acting Beta Agonist Manufacturers by Sales (2017-2022)
3.1.2 Global Ultra Long Acting Beta Agonist Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Ultra Long Acting Beta Agonist in 2021
3.2 Global Ultra Long Acting Beta Agonist Revenue by Manufacturers
3.2.1 Global Ultra Long Acting Beta Agonist Revenue by Manufacturers (2017-2022)
3.2.2 Global Ultra Long Acting Beta Agonist Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Ultra Long Acting Beta Agonist Revenue in 2021
3.3 Global Ultra Long Acting Beta Agonist Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Ultra Long Acting Beta Agonist Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Ultra Long Acting Beta Agonist Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Ultra Long Acting Beta Agonist Sales by Type
4.1.1 Global Ultra Long Acting Beta Agonist Historical Sales by Type (2017-2022)
4.1.2 Global Ultra Long Acting Beta Agonist Forecasted Sales by Type (2023-2028)
4.1.3 Global Ultra Long Acting Beta Agonist Sales Market Share by Type (2017-2028)
4.2 Global Ultra Long Acting Beta Agonist Revenue by Type
4.2.1 Global Ultra Long Acting Beta Agonist Historical Revenue by Type (2017-2022)
4.2.2 Global Ultra Long Acting Beta Agonist Forecasted Revenue by Type (2023-2028)
4.2.3 Global Ultra Long Acting Beta Agonist Revenue Market Share by Type (2017-2028)
4.3 Global Ultra Long Acting Beta Agonist Price by Type
4.3.1 Global Ultra Long Acting Beta Agonist Price by Type (2017-2022)
4.3.2 Global Ultra Long Acting Beta Agonist Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Ultra Long Acting Beta Agonist Sales by Application
5.1.1 Global Ultra Long Acting Beta Agonist Historical Sales by Application (2017-2022)
5.1.2 Global Ultra Long Acting Beta Agonist Forecasted Sales by Application (2023-2028)
5.1.3 Global Ultra Long Acting Beta Agonist Sales Market Share by Application (2017-2028)
5.2 Global Ultra Long Acting Beta Agonist Revenue by Application
5.2.1 Global Ultra Long Acting Beta Agonist Historical Revenue by Application (2017-2022)
5.2.2 Global Ultra Long Acting Beta Agonist Forecasted Revenue by Application (2023-2028)
5.2.3 Global Ultra Long Acting Beta Agonist Revenue Market Share by Application (2017-2028)
5.3 Global Ultra Long Acting Beta Agonist Price by Application
5.3.1 Global Ultra Long Acting Beta Agonist Price by Application (2017-2022)
5.3.2 Global Ultra Long Acting Beta Agonist Price Forecast by Application (2023-2028)
6 North America
6.1 North America Ultra Long Acting Beta Agonist Market Size by Type
6.1.1 North America Ultra Long Acting Beta Agonist Sales by Type (2017-2028)
6.1.2 North America Ultra Long Acting Beta Agonist Revenue by Type (2017-2028)
6.2 North America Ultra Long Acting Beta Agonist Market Size by Application
6.2.1 North America Ultra Long Acting Beta Agonist Sales by Application (2017-2028)
6.2.2 North America Ultra Long Acting Beta Agonist Revenue by Application (2017-2028)
6.3 North America Ultra Long Acting Beta Agonist Market Size by Country
6.3.1 North America Ultra Long Acting Beta Agonist Sales by Country (2017-2028)
6.3.2 North America Ultra Long Acting Beta Agonist Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Ultra Long Acting Beta Agonist Market Size by Type
7.1.1 Europe Ultra Long Acting Beta Agonist Sales by Type (2017-2028)
7.1.2 Europe Ultra Long Acting Beta Agonist Revenue by Type (2017-2028)
7.2 Europe Ultra Long Acting Beta Agonist Market Size by Application
7.2.1 Europe Ultra Long Acting Beta Agonist Sales by Application (2017-2028)
7.2.2 Europe Ultra Long Acting Beta Agonist Revenue by Application (2017-2028)
7.3 Europe Ultra Long Acting Beta Agonist Market Size by Country
7.3.1 Europe Ultra Long Acting Beta Agonist Sales by Country (2017-2028)
7.3.2 Europe Ultra Long Acting Beta Agonist Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Ultra Long Acting Beta Agonist Market Size by Type
8.1.1 Asia Pacific Ultra Long Acting Beta Agonist Sales by Type (2017-2028)
8.1.2 Asia Pacific Ultra Long Acting Beta Agonist Revenue by Type (2017-2028)
8.2 Asia Pacific Ultra Long Acting Beta Agonist Market Size by Application
8.2.1 Asia Pacific Ultra Long Acting Beta Agonist Sales by Application (2017-2028)
8.2.2 Asia Pacific Ultra Long Acting Beta Agonist Revenue by Application (2017-2028)
8.3 Asia Pacific Ultra Long Acting Beta Agonist Market Size by Region
8.3.1 Asia Pacific Ultra Long Acting Beta Agonist Sales by Region (2017-2028)
8.3.2 Asia Pacific Ultra Long Acting Beta Agonist Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Ultra Long Acting Beta Agonist Market Size by Type
9.1.1 Latin America Ultra Long Acting Beta Agonist Sales by Type (2017-2028)
9.1.2 Latin America Ultra Long Acting Beta Agonist Revenue by Type (2017-2028)
9.2 Latin America Ultra Long Acting Beta Agonist Market Size by Application
9.2.1 Latin America Ultra Long Acting Beta Agonist Sales by Application (2017-2028)
9.2.2 Latin America Ultra Long Acting Beta Agonist Revenue by Application (2017-2028)
9.3 Latin America Ultra Long Acting Beta Agonist Market Size by Country
9.3.1 Latin America Ultra Long Acting Beta Agonist Sales by Country (2017-2028)
9.3.2 Latin America Ultra Long Acting Beta Agonist Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Ultra Long Acting Beta Agonist Market Size by Type
10.1.1 Middle East and Africa Ultra Long Acting Beta Agonist Sales by Type (2017-2028)
10.1.2 Middle East and Africa Ultra Long Acting Beta Agonist Revenue by Type (2017-2028)
10.2 Middle East and Africa Ultra Long Acting Beta Agonist Market Size by Application
10.2.1 Middle East and Africa Ultra Long Acting Beta Agonist Sales by Application (2017-2028)
10.2.2 Middle East and Africa Ultra Long Acting Beta Agonist Revenue by Application (2017-2028)
10.3 Middle East and Africa Ultra Long Acting Beta Agonist Market Size by Country
10.3.1 Middle East and Africa Ultra Long Acting Beta Agonist Sales by Country (2017-2028)
10.3.2 Middle East and Africa Ultra Long Acting Beta Agonist Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Sumitomo Dainippon Pharma
11.1.1 Sumitomo Dainippon Pharma Corporation Information
11.1.2 Sumitomo Dainippon Pharma Overview
11.1.3 Sumitomo Dainippon Pharma Ultra Long Acting Beta Agonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Sumitomo Dainippon Pharma Ultra Long Acting Beta Agonist Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Sumitomo Dainippon Pharma Recent Developments
11.2 AstraZeneca
11.2.1 AstraZeneca Corporation Information
11.2.2 AstraZeneca Overview
11.2.3 AstraZeneca Ultra Long Acting Beta Agonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 AstraZeneca Ultra Long Acting Beta Agonist Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 AstraZeneca Recent Developments
11.3 GlaxoSmithKline
11.3.1 GlaxoSmithKline Corporation Information
11.3.2 GlaxoSmithKline Overview
11.3.3 GlaxoSmithKline Ultra Long Acting Beta Agonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 GlaxoSmithKline Ultra Long Acting Beta Agonist Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 GlaxoSmithKline Recent Developments
11.4 Boehringer Ingelheim International
11.4.1 Boehringer Ingelheim International Corporation Information
11.4.2 Boehringer Ingelheim International Overview
11.4.3 Boehringer Ingelheim International Ultra Long Acting Beta Agonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Boehringer Ingelheim International Ultra Long Acting Beta Agonist Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Boehringer Ingelheim International Recent Developments
11.5 Mylan
11.5.1 Mylan Corporation Information
11.5.2 Mylan Overview
11.5.3 Mylan Ultra Long Acting Beta Agonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Mylan Ultra Long Acting Beta Agonist Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Mylan Recent Developments
11.6 Teva
11.6.1 Teva Corporation Information
11.6.2 Teva Overview
11.6.3 Teva Ultra Long Acting Beta Agonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Teva Ultra Long Acting Beta Agonist Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Teva Recent Developments
11.7 Merck
11.7.1 Merck Corporation Information
11.7.2 Merck Overview
11.7.3 Merck Ultra Long Acting Beta Agonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Merck Ultra Long Acting Beta Agonist Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Merck Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Ultra Long Acting Beta Agonist Industry Chain Analysis
12.2 Ultra Long Acting Beta Agonist Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Ultra Long Acting Beta Agonist Production Mode & Process
12.4 Ultra Long Acting Beta Agonist Sales and Marketing
12.4.1 Ultra Long Acting Beta Agonist Sales Channels
12.4.2 Ultra Long Acting Beta Agonist Distributors
12.5 Ultra Long Acting Beta Agonist Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Ultra Long Acting Beta Agonist Industry Trends
13.2 Ultra Long Acting Beta Agonist Market Drivers
13.3 Ultra Long Acting Beta Agonist Market Challenges
13.4 Ultra Long Acting Beta Agonist Market Restraints
14 Key Findings in The Global Ultra Long Acting Beta Agonist Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Tables
Table 1. Global Ultra Long Acting Beta Agonist Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Liquid
Table 3. Major Manufacturers of Tablet
Table 4. Global Ultra Long Acting Beta Agonist Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 5. Global Ultra Long Acting Beta Agonist Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 6. Global Ultra Long Acting Beta Agonist Sales by Region (2017-2022) & (K Units)
Table 7. Global Ultra Long Acting Beta Agonist Sales Market Share by Region (2017-2022)
Table 8. Global Ultra Long Acting Beta Agonist Sales by Region (2023-2028) & (K Units)
Table 9. Global Ultra Long Acting Beta Agonist Sales Market Share by Region (2023-2028)
Table 10. Global Ultra Long Acting Beta Agonist Revenue by Region (2017-2022) & (US$ Million)
Table 11. Global Ultra Long Acting Beta Agonist Revenue Market Share by Region (2017-2022)
Table 12. Global Ultra Long Acting Beta Agonist Revenue by Region (2023-2028) & (US$ Million)
Table 13. Global Ultra Long Acting Beta Agonist Revenue Market Share by Region (2023-2028)
Table 14. Global Ultra Long Acting Beta Agonist Sales by Manufacturers (2017-2022) & (K Units)
Table 15. Global Ultra Long Acting Beta Agonist Sales Share by Manufacturers (2017-2022)
Table 16. Global Ultra Long Acting Beta Agonist Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 17. Global Ultra Long Acting Beta Agonist Revenue Share by Manufacturers (2017-2022)
Table 18. Ultra Long Acting Beta Agonist Price by Manufacturers (2017-2022) &(US$/Unit)
Table 19. Global Ultra Long Acting Beta Agonist Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 20. Global Ultra Long Acting Beta Agonist by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Ultra Long Acting Beta Agonist as of 2021)
Table 21. Ultra Long Acting Beta Agonist Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Ultra Long Acting Beta Agonist Product Offered
Table 23. Date of Manufacturers Enter into Ultra Long Acting Beta Agonist Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Ultra Long Acting Beta Agonist Sales by Type (2017-2022) & (K Units)
Table 26. Global Ultra Long Acting Beta Agonist Sales by Type (2023-2028) & (K Units)
Table 27. Global Ultra Long Acting Beta Agonist Sales Share by Type (2017-2022)
Table 28. Global Ultra Long Acting Beta Agonist Sales Share by Type (2023-2028)
Table 29. Global Ultra Long Acting Beta Agonist Revenue by Type (2017-2022) & (US$ Million)
Table 30. Global Ultra Long Acting Beta Agonist Revenue by Type (2023-2028) & (US$ Million)
Table 31. Global Ultra Long Acting Beta Agonist Revenue Share by Type (2017-2022)
Table 32. Global Ultra Long Acting Beta Agonist Revenue Share by Type (2023-2028)
Table 33. Ultra Long Acting Beta Agonist Price by Type (2017-2022) & (US$/Unit)
Table 34. Global Ultra Long Acting Beta Agonist Price Forecast by Type (2023-2028) & (US$/Unit)
Table 35. Global Ultra Long Acting Beta Agonist Sales by Application (2017-2022) & (K Units)
Table 36. Global Ultra Long Acting Beta Agonist Sales by Application (2023-2028) & (K Units)
Table 37. Global Ultra Long Acting Beta Agonist Sales Share by Application (2017-2022)
Table 38. Global Ultra Long Acting Beta Agonist Sales Share by Application (2023-2028)
Table 39. Global Ultra Long Acting Beta Agonist Revenue by Application (2017-2022) & (US$ Million)
Table 40. Global Ultra Long Acting Beta Agonist Revenue by Application (2023-2028) & (US$ Million)
Table 41. Global Ultra Long Acting Beta Agonist Revenue Share by Application (2017-2022)
Table 42. Global Ultra Long Acting Beta Agonist Revenue Share by Application (2023-2028)
Table 43. Ultra Long Acting Beta Agonist Price by Application (2017-2022) & (US$/Unit)
Table 44. Global Ultra Long Acting Beta Agonist Price Forecast by Application (2023-2028) & (US$/Unit)
Table 45. North America Ultra Long Acting Beta Agonist Sales by Type (2017-2022) & (K Units)
Table 46. North America Ultra Long Acting Beta Agonist Sales by Type (2023-2028) & (K Units)
Table 47. North America Ultra Long Acting Beta Agonist Revenue by Type (2017-2022) & (US$ Million)
Table 48. North America Ultra Long Acting Beta Agonist Revenue by Type (2023-2028) & (US$ Million)
Table 49. North America Ultra Long Acting Beta Agonist Sales by Application (2017-2022) & (K Units)
Table 50. North America Ultra Long Acting Beta Agonist Sales by Application (2023-2028) & (K Units)
Table 51. North America Ultra Long Acting Beta Agonist Revenue by Application (2017-2022) & (US$ Million)
Table 52. North America Ultra Long Acting Beta Agonist Revenue by Application (2023-2028) & (US$ Million)
Table 53. North America Ultra Long Acting Beta Agonist Sales by Country (2017-2022) & (K Units)
Table 54. North America Ultra Long Acting Beta Agonist Sales by Country (2023-2028) & (K Units)
Table 55. North America Ultra Long Acting Beta Agonist Revenue by Country (2017-2022) & (US$ Million)
Table 56. North America Ultra Long Acting Beta Agonist Revenue by Country (2023-2028) & (US$ Million)
Table 57. Europe Ultra Long Acting Beta Agonist Sales by Type (2017-2022) & (K Units)
Table 58. Europe Ultra Long Acting Beta Agonist Sales by Type (2023-2028) & (K Units)
Table 59. Europe Ultra Long Acting Beta Agonist Revenue by Type (2017-2022) & (US$ Million)
Table 60. Europe Ultra Long Acting Beta Agonist Revenue by Type (2023-2028) & (US$ Million)
Table 61. Europe Ultra Long Acting Beta Agonist Sales by Application (2017-2022) & (K Units)
Table 62. Europe Ultra Long Acting Beta Agonist Sales by Application (2023-2028) & (K Units)
Table 63. Europe Ultra Long Acting Beta Agonist Revenue by Application (2017-2022) & (US$ Million)
Table 64. Europe Ultra Long Acting Beta Agonist Revenue by Application (2023-2028) & (US$ Million)
Table 65. Europe Ultra Long Acting Beta Agonist Sales by Country (2017-2022) & (K Units)
Table 66. Europe Ultra Long Acting Beta Agonist Sales by Country (2023-2028) & (K Units)
Table 67. Europe Ultra Long Acting Beta Agonist Revenue by Country (2017-2022) & (US$ Million)
Table 68. Europe Ultra Long Acting Beta Agonist Revenue by Country (2023-2028) & (US$ Million)
Table 69. Asia Pacific Ultra Long Acting Beta Agonist Sales by Type (2017-2022) & (K Units)
Table 70. Asia Pacific Ultra Long Acting Beta Agonist Sales by Type (2023-2028) & (K Units)
Table 71. Asia Pacific Ultra Long Acting Beta Agonist Revenue by Type (2017-2022) & (US$ Million)
Table 72. Asia Pacific Ultra Long Acting Beta Agonist Revenue by Type (2023-2028) & (US$ Million)
Table 73. Asia Pacific Ultra Long Acting Beta Agonist Sales by Application (2017-2022) & (K Units)
Table 74. Asia Pacific Ultra Long Acting Beta Agonist Sales by Application (2023-2028) & (K Units)
Table 75. Asia Pacific Ultra Long Acting Beta Agonist Revenue by Application (2017-2022) & (US$ Million)
Table 76. Asia Pacific Ultra Long Acting Beta Agonist Revenue by Application (2023-2028) & (US$ Million)
Table 77. Asia Pacific Ultra Long Acting Beta Agonist Sales by Region (2017-2022) & (K Units)
Table 78. Asia Pacific Ultra Long Acting Beta Agonist Sales by Region (2023-2028) & (K Units)
Table 79. Asia Pacific Ultra Long Acting Beta Agonist Revenue by Region (2017-2022) & (US$ Million)
Table 80. Asia Pacific Ultra Long Acting Beta Agonist Revenue by Region (2023-2028) & (US$ Million)
Table 81. Latin America Ultra Long Acting Beta Agonist Sales by Type (2017-2022) & (K Units)
Table 82. Latin America Ultra Long Acting Beta Agonist Sales by Type (2023-2028) & (K Units)
Table 83. Latin America Ultra Long Acting Beta Agonist Revenue by Type (2017-2022) & (US$ Million)
Table 84. Latin America Ultra Long Acting Beta Agonist Revenue by Type (2023-2028) & (US$ Million)
Table 85. Latin America Ultra Long Acting Beta Agonist Sales by Application (2017-2022) & (K Units)
Table 86. Latin America Ultra Long Acting Beta Agonist Sales by Application (2023-2028) & (K Units)
Table 87. Latin America Ultra Long Acting Beta Agonist Revenue by Application (2017-2022) & (US$ Million)
Table 88. Latin America Ultra Long Acting Beta Agonist Revenue by Application (2023-2028) & (US$ Million)
Table 89. Latin America Ultra Long Acting Beta Agonist Sales by Country (2017-2022) & (K Units)
Table 90. Latin America Ultra Long Acting Beta Agonist Sales by Country (2023-2028) & (K Units)
Table 91. Latin America Ultra Long Acting Beta Agonist Revenue by Country (2017-2022) & (US$ Million)
Table 92. Latin America Ultra Long Acting Beta Agonist Revenue by Country (2023-2028) & (US$ Million)
Table 93. Middle East and Africa Ultra Long Acting Beta Agonist Sales by Type (2017-2022) & (K Units)
Table 94. Middle East and Africa Ultra Long Acting Beta Agonist Sales by Type (2023-2028) & (K Units)
Table 95. Middle East and Africa Ultra Long Acting Beta Agonist Revenue by Type (2017-2022) & (US$ Million)
Table 96. Middle East and Africa Ultra Long Acting Beta Agonist Revenue by Type (2023-2028) & (US$ Million)
Table 97. Middle East and Africa Ultra Long Acting Beta Agonist Sales by Application (2017-2022) & (K Units)
Table 98. Middle East and Africa Ultra Long Acting Beta Agonist Sales by Application (2023-2028) & (K Units)
Table 99. Middle East and Africa Ultra Long Acting Beta Agonist Revenue by Application (2017-2022) & (US$ Million)
Table 100. Middle East and Africa Ultra Long Acting Beta Agonist Revenue by Application (2023-2028) & (US$ Million)
Table 101. Middle East and Africa Ultra Long Acting Beta Agonist Sales by Country (2017-2022) & (K Units)
Table 102. Middle East and Africa Ultra Long Acting Beta Agonist Sales by Country (2023-2028) & (K Units)
Table 103. Middle East and Africa Ultra Long Acting Beta Agonist Revenue by Country (2017-2022) & (US$ Million)
Table 104. Middle East and Africa Ultra Long Acting Beta Agonist Revenue by Country (2023-2028) & (US$ Million)
Table 105. Sumitomo Dainippon Pharma Corporation Information
Table 106. Sumitomo Dainippon Pharma Description and Major Businesses
Table 107. Sumitomo Dainippon Pharma Ultra Long Acting Beta Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 108. Sumitomo Dainippon Pharma Ultra Long Acting Beta Agonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 109. Sumitomo Dainippon Pharma Recent Developments
Table 110. AstraZeneca Corporation Information
Table 111. AstraZeneca Description and Major Businesses
Table 112. AstraZeneca Ultra Long Acting Beta Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 113. AstraZeneca Ultra Long Acting Beta Agonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 114. AstraZeneca Recent Developments
Table 115. GlaxoSmithKline Corporation Information
Table 116. GlaxoSmithKline Description and Major Businesses
Table 117. GlaxoSmithKline Ultra Long Acting Beta Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 118. GlaxoSmithKline Ultra Long Acting Beta Agonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 119. GlaxoSmithKline Recent Developments
Table 120. Boehringer Ingelheim International Corporation Information
Table 121. Boehringer Ingelheim International Description and Major Businesses
Table 122. Boehringer Ingelheim International Ultra Long Acting Beta Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 123. Boehringer Ingelheim International Ultra Long Acting Beta Agonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 124. Boehringer Ingelheim International Recent Developments
Table 125. Mylan Corporation Information
Table 126. Mylan Description and Major Businesses
Table 127. Mylan Ultra Long Acting Beta Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 128. Mylan Ultra Long Acting Beta Agonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 129. Mylan Recent Developments
Table 130. Teva Corporation Information
Table 131. Teva Description and Major Businesses
Table 132. Teva Ultra Long Acting Beta Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 133. Teva Ultra Long Acting Beta Agonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 134. Teva Recent Developments
Table 135. Merck Corporation Information
Table 136. Merck Description and Major Businesses
Table 137. Merck Ultra Long Acting Beta Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 138. Merck Ultra Long Acting Beta Agonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 139. Merck Recent Developments
Table 140. Key Raw Materials Lists
Table 141. Raw Materials Key Suppliers Lists
Table 142. Ultra Long Acting Beta Agonist Distributors List
Table 143. Ultra Long Acting Beta Agonist Customers List
Table 144. Ultra Long Acting Beta Agonist Market Trends
Table 145. Ultra Long Acting Beta Agonist Market Drivers
Table 146. Ultra Long Acting Beta Agonist Market Challenges
Table 147. Ultra Long Acting Beta Agonist Market Restraints
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
List of Figures
Figure 1. Ultra Long Acting Beta Agonist Product Picture
Figure 3. Global Ultra Long Acting Beta Agonist Market Share by Type in 2021 & 2028
Figure 3. Liquid Product Picture
Figure 4. Tablet Product Picture
Figure 5. Global Ultra Long Acting Beta Agonist Market Share by Application in 2021 & 2028
Figure 6. Hospitals
Figure 7. Clinics
Figure 8. Ambulatory Surgical Center
Figure 9. Others
Figure 10. Ultra Long Acting Beta Agonist Report Years Considered
Figure 11. Global Ultra Long Acting Beta Agonist Sales 2017-2028 (K Units)
Figure 12. Global Ultra Long Acting Beta Agonist Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 13. Global Ultra Long Acting Beta Agonist Revenue 2017-2028 (US$ Million)
Figure 14. Global Ultra Long Acting Beta Agonist Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 15. Global Ultra Long Acting Beta Agonist Sales Market Share by Region (2017-2022)
Figure 16. Global Ultra Long Acting Beta Agonist Sales Market Share by Region (2023-2028)
Figure 17. North America Ultra Long Acting Beta Agonist Sales YoY (2017-2028) & (K Units)
Figure 18. North America Ultra Long Acting Beta Agonist Revenue YoY (2017-2028) & (US$ Million)
Figure 19. Europe Ultra Long Acting Beta Agonist Sales YoY (2017-2028) & (K Units)
Figure 20. Europe Ultra Long Acting Beta Agonist Revenue YoY (2017-2028) & (US$ Million)
Figure 21. Asia-Pacific Ultra Long Acting Beta Agonist Sales YoY (2017-2028) & (K Units)
Figure 22. Asia-Pacific Ultra Long Acting Beta Agonist Revenue YoY (2017-2028) & (US$ Million)
Figure 23. Latin America Ultra Long Acting Beta Agonist Sales YoY (2017-2028) & (K Units)
Figure 24. Latin America Ultra Long Acting Beta Agonist Revenue YoY (2017-2028) & (US$ Million)
Figure 25. Middle East & Africa Ultra Long Acting Beta Agonist Sales YoY (2017-2028) & (K Units)
Figure 26. Middle East & Africa Ultra Long Acting Beta Agonist Revenue YoY (2017-2028) & (US$ Million)
Figure 27. The Ultra Long Acting Beta Agonist Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 28. The Top 5 and 10 Largest Manufacturers of Ultra Long Acting Beta Agonist in the World: Market Share by Ultra Long Acting Beta Agonist Revenue in 2021
Figure 29. Global Ultra Long Acting Beta Agonist Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 30. Global Ultra Long Acting Beta Agonist Sales Market Share by Type (2017-2028)
Figure 31. Global Ultra Long Acting Beta Agonist Revenue Market Share by Type (2017-2028)
Figure 32. Global Ultra Long Acting Beta Agonist Sales Market Share by Application (2017-2028)
Figure 33. Global Ultra Long Acting Beta Agonist Revenue Market Share by Application (2017-2028)
Figure 34. North America Ultra Long Acting Beta Agonist Sales Market Share by Type (2017-2028)
Figure 35. North America Ultra Long Acting Beta Agonist Revenue Market Share by Type (2017-2028)
Figure 36. North America Ultra Long Acting Beta Agonist Sales Market Share by Application (2017-2028)
Figure 37. North America Ultra Long Acting Beta Agonist Revenue Market Share by Application (2017-2028)
Figure 38. North America Ultra Long Acting Beta Agonist Sales Share by Country (2017-2028)
Figure 39. North America Ultra Long Acting Beta Agonist Revenue Share by Country (2017-2028)
Figure 40. United States Ultra Long Acting Beta Agonist Revenue (2017-2028) & (US$ Million)
Figure 41. Canada Ultra Long Acting Beta Agonist Revenue (2017-2028) & (US$ Million)
Figure 42. Europe Ultra Long Acting Beta Agonist Sales Market Share by Type (2017-2028)
Figure 43. Europe Ultra Long Acting Beta Agonist Revenue Market Share by Type (2017-2028)
Figure 44. Europe Ultra Long Acting Beta Agonist Sales Market Share by Application (2017-2028)
Figure 45. Europe Ultra Long Acting Beta Agonist Revenue Market Share by Application (2017-2028)
Figure 46. Europe Ultra Long Acting Beta Agonist Sales Share by Country (2017-2028)
Figure 47. Europe Ultra Long Acting Beta Agonist Revenue Share by Country (2017-2028)
Figure 48. Germany Ultra Long Acting Beta Agonist Revenue (2017-2028) & (US$ Million)
Figure 49. France Ultra Long Acting Beta Agonist Revenue (2017-2028) & (US$ Million)
Figure 50. U.K. Ultra Long Acting Beta Agonist Revenue (2017-2028) & (US$ Million)
Figure 51. Italy Ultra Long Acting Beta Agonist Revenue (2017-2028) & (US$ Million)
Figure 52. Russia Ultra Long Acting Beta Agonist Revenue (2017-2028) & (US$ Million)
Figure 53. Asia Pacific Ultra Long Acting Beta Agonist Sales Market Share by Type (2017-2028)
Figure 54. Asia Pacific Ultra Long Acting Beta Agonist Revenue Market Share by Type (2017-2028)
Figure 55. Asia Pacific Ultra Long Acting Beta Agonist Sales Market Share by Application (2017-2028)
Figure 56. Asia Pacific Ultra Long Acting Beta Agonist Revenue Market Share by Application (2017-2028)
Figure 57. Asia Pacific Ultra Long Acting Beta Agonist Sales Share by Region (2017-2028)
Figure 58. Asia Pacific Ultra Long Acting Beta Agonist Revenue Share by Region (2017-2028)
Figure 59. China Ultra Long Acting Beta Agonist Revenue (2017-2028) & (US$ Million)
Figure 60. Japan Ultra Long Acting Beta Agonist Revenue (2017-2028) & (US$ Million)
Figure 61. South Korea Ultra Long Acting Beta Agonist Revenue (2017-2028) & (US$ Million)
Figure 62. India Ultra Long Acting Beta Agonist Revenue (2017-2028) & (US$ Million)
Figure 63. Australia Ultra Long Acting Beta Agonist Revenue (2017-2028) & (US$ Million)
Figure 64. China Taiwan Ultra Long Acting Beta Agonist Revenue (2017-2028) & (US$ Million)
Figure 65. Indonesia Ultra Long Acting Beta Agonist Revenue (2017-2028) & (US$ Million)
Figure 66. Thailand Ultra Long Acting Beta Agonist Revenue (2017-2028) & (US$ Million)
Figure 67. Malaysia Ultra Long Acting Beta Agonist Revenue (2017-2028) & (US$ Million)
Figure 68. Latin America Ultra Long Acting Beta Agonist Sales Market Share by Type (2017-2028)
Figure 69. Latin America Ultra Long Acting Beta Agonist Revenue Market Share by Type (2017-2028)
Figure 70. Latin America Ultra Long Acting Beta Agonist Sales Market Share by Application (2017-2028)
Figure 71. Latin America Ultra Long Acting Beta Agonist Revenue Market Share by Application (2017-2028)
Figure 72. Latin America Ultra Long Acting Beta Agonist Sales Share by Country (2017-2028)
Figure 73. Latin America Ultra Long Acting Beta Agonist Revenue Share by Country (2017-2028)
Figure 74. Mexico Ultra Long Acting Beta Agonist Revenue (2017-2028) & (US$ Million)
Figure 75. Brazil Ultra Long Acting Beta Agonist Revenue (2017-2028) & (US$ Million)
Figure 76. Argentina Ultra Long Acting Beta Agonist Revenue (2017-2028) & (US$ Million)
Figure 77. Middle East and Africa Ultra Long Acting Beta Agonist Sales Market Share by Type (2017-2028)
Figure 78. Middle East and Africa Ultra Long Acting Beta Agonist Revenue Market Share by Type (2017-2028)
Figure 79. Middle East and Africa Ultra Long Acting Beta Agonist Sales Market Share by Application (2017-2028)
Figure 80. Middle East and Africa Ultra Long Acting Beta Agonist Revenue Market Share by Application (2017-2028)
Figure 81. Middle East and Africa Ultra Long Acting Beta Agonist Sales Share by Country (2017-2028)
Figure 82. Middle East and Africa Ultra Long Acting Beta Agonist Revenue Share by Country (2017-2028)
Figure 83. Turkey Ultra Long Acting Beta Agonist Revenue (2017-2028) & (US$ Million)
Figure 84. Saudi Arabia Ultra Long Acting Beta Agonist Revenue (2017-2028) & (US$ Million)
Figure 85. UAE Ultra Long Acting Beta Agonist Revenue (2017-2028) & (US$ Million)
Figure 86. Ultra Long Acting Beta Agonist Value Chain
Figure 87. Ultra Long Acting Beta Agonist Production Process
Figure 88. Channels of Distribution
Figure 89. Distributors Profiles
Figure 90. Bottom-up and Top-down Approaches for This Report
Figure 91. Data Triangulation
Figure 92. Key Executives Interviewed

---